These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22990124)

  • 21. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
    Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
    ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug delivery from ordered mesoporous matrices.
    Manzano M; Colilla M; Vallet-Regí M
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1383-400. PubMed ID: 19941412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple way to obtain pH-sensitive drug release from functional mesoporous silica materials.
    Xiang D; Lin H; Guo W; Ma J; Cui L; Jiang J; Qu F
    IET Nanobiotechnol; 2014 Dec; 8(4):179-83. PubMed ID: 25429494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: opportunities and challenges.
    Bremmell KE; Prestidge CA
    Drug Dev Ind Pharm; 2019 Mar; 45(3):349-358. PubMed ID: 30411991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems.
    Hate SS; Reutzel-Edens SM; Taylor LS
    Mol Pharm; 2020 Sep; 17(9):3435-3446. PubMed ID: 32790416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesoporous systems for poorly soluble drugs - recent trends.
    Riikonen J; Xu W; Lehto VP
    Int J Pharm; 2018 Jan; 536(1):178-186. PubMed ID: 29183856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
    Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
    Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
    Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
    Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides".
    Bernardos A; Mondragon L; Aznar E; Marcos MD; Martinez-Mañez R; Sancenon F; Soto J; Barat JM; Perez-Paya E; Guillem C; Amoros P
    ACS Nano; 2010 Nov; 4(11):6353-68. PubMed ID: 20958020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers.
    Florek J; Caillard R; Kleitz F
    Nanoscale; 2017 Oct; 9(40):15252-15277. PubMed ID: 28984885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs.
    Van Speybroeck M; Barillaro V; Thi TD; Mellaerts R; Martens J; Van Humbeeck J; Vermant J; Annaert P; Van den Mooter G; Augustijns P
    J Pharm Sci; 2009 Aug; 98(8):2648-58. PubMed ID: 19072861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery.
    Zhao Y; Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
    Expert Opin Drug Deliv; 2010 Sep; 7(9):1013-29. PubMed ID: 20716017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesoporous inorganic nanoscale particles for drug adsorption and controlled release.
    Cavallaro G; Lazzara G; Fakhrullin R
    Ther Deliv; 2018 Mar; 9(4):287-301. PubMed ID: 29495930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysozyme as a pH-responsive valve for the controlled release of guest molecules from mesoporous silica.
    Xue M; Findenegg GH
    Langmuir; 2012 Dec; 28(50):17578-84. PubMed ID: 23173551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adsorption and release of biocides with mesoporous silica nanoparticles.
    Popat A; Liu J; Hu Q; Kennedy M; Peters B; Lu GQ; Qiao SZ
    Nanoscale; 2012 Feb; 4(3):970-5. PubMed ID: 22200056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesoporous silica material TUD-1 as a drug delivery system.
    Heikkilä T; Salonen J; Tuura J; Hamdy MS; Mul G; Kumar N; Salmi T; Murzin DY; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Feb; 331(1):133-8. PubMed ID: 17046183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesoporous Drug Delivery System: From Physical Properties of Drug in Solid State to Controlled Release.
    Wang Y; Li F; Xin J; Xu J; Yu G; Shi Q
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles.
    Limnell T; Heikkilä T; Santos HA; Sistonen S; Hellstén S; Laaksonen T; Peltonen L; Kumar N; Murzin DY; Louhi-Kultanen M; Salonen J; Hirvonen J; Lehto VP
    Int J Pharm; 2011 Sep; 416(1):242-51. PubMed ID: 21763766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesoporous silica nanoparticles as nanocarriers.
    Wu SH; Hung Y; Mou CY
    Chem Commun (Camb); 2011 Sep; 47(36):9972-85. PubMed ID: 21716992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.